Unveiling the Power of Nabsys' OhmX™ Platform: A Game-Changer in Genetic Disorder Diagnosis and Research
The Future of Genetic Analysis is Here!
Nabsys 2.0, a leader in electronic genome mapping, has taken center stage at the American Society of Human Genetics (ASHG) 2025 Annual Meeting, showcasing its groundbreaking OhmX™ Platform. This innovative technology is revolutionizing the way we approach undiagnosed disorders and optimizing research workflows.
But here's where it gets controversial... Can a single platform truly make such a significant impact on genetic research and diagnosis?
In collaboration with Boston Children's Hospital, Nabsys presented real-world applications of the OhmX Platform, demonstrating its ability to accurately identify structural variants in undiagnosed disorders. The session, held on a Google Colaboratory platform, reviewed the implementation of electronic genome mapping (EGM) technology in a tertiary children's hospital setting.
Dr. Catherine Brownstein from Boston Children's Hospital highlighted the impact of Nabsys' EGM technology, stating, "It has provided us with unprecedented insights into structural variations, becoming an essential tool for understanding the underlying causes of rare and complex diseases."
Barrett Bready, M.D., founder and CEO of Nabsys, emphasized the importance of speed and accuracy in whole-genome structural variation research. He said, "Our presentations at ASHG this year showcase the real-world impact of the OhmX Platform. We are excited to share additional data, demonstrating our platform's ability to transform genome mapping."
Nabsys also presented new findings in a poster titled, "Accelerated Electronic Genome Mapping with Simultaneous Dual Nicking & Labeling." This research highlights a novel approach to EGM sample preparation, significantly reducing time and complexity while improving structural variant calling.
Jay Sage, Ph.D., Senior Director of Assay Development at Nabsys, explained, "Streamlined workflows are crucial for timely and accurate results, especially in time-sensitive medical situations. Our SNL workflows and heat-free processes enhance the OhmX Platform's ability to identify disease-driving structural variants, offering a more comprehensive understanding of the human genome."
And this is the part most people miss... The potential impact of these advancements on patient care and research is immense. Nabsys' presentations and research provide a glimpse into the future of genomics, where accurate and efficient analysis of structural variations could lead to faster diagnoses and improved patient outcomes.
For more information and to access the presentations, visit Nabsys' website at www.nabsys.com/resources?category=Posters.
Nabsys has announced a total of eight EGM presentations at the ASHG Meeting, highlighting its commitment to advancing genetic research and diagnosis. The full list of presentations is available on their website.
About Nabsys 2.0, LLC
Nabsys' mission is to enhance our understanding of diseases, improve diagnostic rates, and ultimately, patient outcomes. By enabling routine and cost-effective analysis of genomic structural variation, they are dedicated to pushing the boundaries of genomic analysis.
To learn more, visit https://www.nabsys.com.
